health-it is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Tej Tadi, the most common co-covered peer. Each story carries 2 original sources on average, compared with 3.3 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about MindMaze Therapeutics
health-it is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Tej Tadi, the most common co-covered peer. Each story carries 2 original sources on average, compared with 3.3 for the broader beat in this window. At 5, the average consequence score sits below the same-window beat average of 5.9. MindMaze Therapeutics appears in 1 tracked Healthcare story from March 12, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 38 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering MindMaze Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
MindMaze Therapeutics has appointed healthtech veteran Zach Henderson as its new CEO, signaling a pivot from research-heavy development to aggressive global commercialization. Henderson will lead the digital neurotherapeutics unicorn as it seeks to scale its VR-based brain repair platforms across international healthcare systems.